Asunto(s)
Analgésicos Opioides/farmacología , Meperidina/análogos & derivados , Meperidina/farmacología , Morfina/farmacología , Dolor/tratamiento farmacológico , Enfermedad Aguda , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/farmacocinética , Interacciones Farmacológicas , Humanos , Meperidina/efectos adversos , Meperidina/farmacocinética , Morfina/efectos adversos , Morfina/farmacocinéticaRESUMEN
Methotrexate (MTX) steady state concentrations were evaluated in 42 children who had received high-dose infusions (6-8 g/m2) for acute lymphocytic leukemia. Concentrations in serum and cerebrospinal fluid (CSF) measured by immunoassay were found to be highly variable. Reanalysis by a reference high-pressure liquid chromatography method ruled out analytical factors as a source of this variability. The correlation coefficient between the analytical methods was 0.77 for the serum data and 0.88 for the CSF data. The variability of serum and CSF concentrations was higher in younger patients (serum; P = 0.05 and CSF; P = 0.18), and the CSF concentration decreased with decreasing age and in later courses. Body surface area, body mass index, weight, and gender were not significantly related to MTX variability. We conclude that the pronounced pharmacokinetic variability seen during MTX infusions remains largely unexplained.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Metotrexato/farmacocinética , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/sangre , Antimetabolitos Antineoplásicos/líquido cefalorraquídeo , Niño , Preescolar , Cromatografía Líquida de Alta Presión , Humanos , Infusiones Intravenosas , Metotrexato/administración & dosificación , Metotrexato/sangre , Metotrexato/líquido cefalorraquídeo , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangre , Leucemia-Linfoma Linfoblástico de Células Precursoras/líquido cefalorraquídeo , Técnicas Psicológicas/normasRESUMEN
A method for the simultaneous determination of the three selective serotonin reuptake inhibitors (SSRIs) citalopram, fluoxetine, paroxetine and their metabolites in whole blood and plasma was developed. Sample clean-up and separation were achieved using a solid-phase extraction method with C8 non-endcapped columns followed by reversed-phase high-performance liquid chromatography with fluorescence and ultraviolet detection. The robustness of the solid-phase extraction method was tested for citalopram, fluoxetine, paroxetine, Cl-citalopram and the internal standard, protriptyline, using a fractional factorial design with nine factors at two levels. The fractional factorial design showed two significant effects for paroxetine in whole blood. The robustness testing for citalopram, fluoxetine, Cl-citalopram and the internal standard revealed no significant main effects in whole blood and plasma. The optimization and the robustness of the high-performance liquid chromatographic separation were investigated with regard to pH and relative amount of acetonitrile in the mobile phase by a central composite design circumscribed. No alteration in the elution order and no significant change in resolution for a deviation of +/-1% acetonitrile and +/-0.3 pH units from the specified conditions were observed. The method was validated for the concentration range 0.050-5.0 micromol/l with fluorescence detection and 0.12-5.0 micromol/l with ultraviolet detection. The limits of quantitation were 0.025 micromol/l for citalopram and paroxetine, 0.050 micromol/l for desmethyl citalopram, di-desmethyl citalopram and citalopram-N-oxide, 0.12 micromol/l for the paroxetine metabolites by fluorescence detection, and 0.10 micromol/l for fluoxetine and norfluoxetine by ultraviolet detection. Relative standard deviations for the within-day and between-day precision were in the ranges 1.4-10.6% and 3.1-20.3%, respectively. Recoveries were in the 63-114% range for citalopram, fluoxetine and paroxetine, and in the 38-95% range for the metabolites. The method has been used for the analysis of whole blood and plasma samples from SSRI-exposed patients and forensic cases.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Citalopram/sangre , Fluoxetina/sangre , Paroxetina/sangre , Inhibidores Selectivos de la Recaptación de Serotonina/sangre , Acetonitrilos , Humanos , Concentración de Iones de Hidrógeno , Control de Calidad , Sensibilidad y Especificidad , Espectrometría de Fluorescencia , Espectrofotometría UltravioletaRESUMEN
PURPOSE/METHODS: Twenty-four patients (17 males and 7 females with a mean age of 54 years) with malignant lymphoma participated in a study of doxorubicin pharmacokinetics after 50 mg/m(2) as 10-min infusions. In addition to plasma samples, serial leukocyte samples and - in one subject - serial biopsy specimens from lymphoma infiltrates were obtained. The samples were analysed by reversed-phase high-performance liquid chromatography. RESULTS: In contrast to several previous studies, the data suggested that 7-deoxydoxorubicinolone, and not doxorubicinone, is a metabolite of doxorubicin in humans. Doxorubicin, but no metabolites, was present in significant and fairly constant concentrations in circulating leukocytes. These levels may reflect the drug levels in lymphoma infiltrates. The data further suggest that metabolism to 7-deoxydoxorubicinone is subject to large interindividual variation, possibly due to a genetic polymorphism, and that significant levels of a metabolic product which may be a doxorubicin glucuronide can be recovered from plasma of patients treated with doxorubicin.
Asunto(s)
Doxorrubicina/farmacocinética , Linfoma/sangre , Adulto , Anciano , Área Bajo la Curva , Biotransformación , Doxorrubicina/administración & dosificación , Doxorrubicina/análogos & derivados , Doxorrubicina/sangre , Doxorrubicina/uso terapéutico , Femenino , Humanos , Infusiones Intravenosas , Leucocitos Mononucleares/metabolismo , Linfoma/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Naftacenos/sangre , Factores de TiempoRESUMEN
The aim of this study was to investigate the postmortem redistribution of several drugs in a rat model and to examine if any of the pharmacological properties was related to the extent of this phenomenon. One of the following drugs: phenobarbital (phenobarbitone), acetaminophen (paracetamol), carbamazepine, codeine, verapamil, amphetamine, mianserin, trimeprazine (alimemazine) or chloroquine was administered together with nortriptyline orally to rats 90 min prior to sacrifice. Heart blood was sampled immediately before sacrifice and after 2 h postmortem, as it has previously been shown that this is sufficient time for postmortem concentration changes to occur in heart blood. Blood was also sampled from the clamped abdominal inferior vena cava (representing peripheral blood) and tissue samples were taken from lungs, myocardium, liver, kidney, thigh muscle, forebrain, and vitreous humor together with a specimen from the minced carcass. Drugs were analyzed by high performance liquid or gas chromatography. For phenobarbital, acetaminophen and carbamazepine the postmortem to antemortem blood drug concentration ratios were close to 1.0 and tissue concentrations were low. The postmortem to antemortem heart blood drug concentration ratio for chloroquine (6.9 +/- 1.5) was higher than for nortriptyline (3.5 +/- 0.3), and the remaining drugs (codeine, verapamil, amphetamine, mianserin, and trimeprazine) showed ratios of the same magnitude as nortriptyline. The postmortem to antemortem blood drug concentration ratios for both heart blood and blood from the vena cava and also the lung to antemortem blood drug concentration ratio were closely related to the apparent volume of distribution for the drugs studied (p < 0.001). Accordingly, an apparent volume of distribution of more than 3-4 L/kg is a good predictor that a drug is liable to undergo postmortem redistribution with significant increments in blood levels. The postmortem drug concentration in blood from vena cava was closely related to the antemortem blood level, confirming that among the postmortem samples, the peripheral blood sample was the most representative for the antemortem blood concentration.
Asunto(s)
Preparaciones Farmacéuticas/metabolismo , Farmacocinética , Cambios Post Mortem , Animales , Medicina Legal/métodos , Masculino , Ratas , Ratas Wistar , Distribución TisularAsunto(s)
Antiparkinsonianos/efectos adversos , Antipsicóticos/efectos adversos , Antiparkinsonianos/envenenamiento , Antipsicóticos/envenenamiento , Benzotropina/efectos adversos , Benzotropina/envenenamiento , Biperideno/efectos adversos , Biperideno/envenenamiento , Humanos , Orfenadrina/efectos adversos , Orfenadrina/envenenamientoRESUMEN
The air pollution dispersion model EPISODE has been developed at the Norwegian Institute for Air Research (NILU) over the past several years in order to meet the needs of modern air quality management work in urban areas. The model has recently been used as a basis for exposure calculations of NOx and NO2 in order to assess the effects of different traffic diversion measures on health and well being for the residents in the Vålerenga-Ekeberg-Gamlebyen area in Oslo. Here we describe some results from the most recent evaluations of the model for NOx and NO2 at station Nordahl Brunsgate in Oslo for the period 1 October 1996-19 November 1996. In addition examples of population exposure calculations for Oslo performed during the winter period of 1995-96, are also presented.
Asunto(s)
Contaminación del Aire/análisis , Exposición a Riesgos Ambientales , Monitoreo del Ambiente/métodos , Modelos Teóricos , Movimientos del Aire , Humanos , Salud Pública , Estaciones del Año , Población Urbana , Emisiones de Vehículos/análisisRESUMEN
In this study we have evaluated the postmortem pharmacokinetics of amitriptyline (Ami) and metabolites in pigs after oral and intravenous administration, and the results are compared with previous studies in rats and humans. In addition a meticulous investigation of blood and tissue concentrations after postmortem intravenous infusion of Ami was undertaken. Of a total of 9 over-night fasted pigs, 3 were given 25 mg/Kg Ami orally, and another 3 pigs received an intravenous infusion lasting 1 h of 3.3 mg/Kg Ami prior to death. The final 3 pigs were sacrificed and then given the intravenous infusion after death. After approximately 5 h at room temperature, all carcasses were subsequently stored at 4-5 degrees C. Postmortem blood samples were collected at 0.25, 1, 2, 4, 8, 24, 48, and 96 h through an indwelling intracardial needle. Postmortem examination with blood and tissue sampling was performed 96 h after death. Analysis was carried out by high performance liquid chromatography with ultraviolet detection. Postmortem blood samples from the heart of the orally dosed animals revealed large and variable concentration increases of 99(30-243)% for Ami and 96(52-429)% for the main metabolite 10-OH-Ami at 96 h. In the intravenously infused live pigs heart blood Ami increased by 55(33-69)% and 10-OH-Ami increased by 232(76-240)%. Blood from the atria had significantly higher Ami concentrations than blood from both ventricles in the animals dosed while alive, and the drug concentration in femoral blood was higher than in heart blood (p < 0.01). In the orally dosed pigs the left lobe of the liver had significantly higher Ami levels than the right lobe. Tissue/blood Ami concentration ratios were generally lower than previously reported in rats and approximating the levels reported in humans. The animals infused intravenously after death demonstrated high drug levels in blood samples from central vessels, heart, lungs as well as cerebrospinal fluid and vitreous humour. This implies that the presence of a lethal concentration of a drug in just one sample of heart blood can prove worthless in a case where agonal drug infusion may have occurred.
Asunto(s)
Amitriptilina/farmacocinética , Antidepresivos Tricíclicos/farmacocinética , Cambios Post Mortem , Porcinos/metabolismo , Administración Oral , Amitriptilina/administración & dosificación , Animales , Antidepresivos Tricíclicos/administración & dosificación , Cromatografía Líquida de Alta Presión , Humanos , Infusiones Intravenosas , Ratas , Distribución TisularRESUMEN
All autopsy samples received at the National Institute of Forensic Toxicology during the years 1986-1996 which contained anticholinergic antiparkinsonian drugs were reviewed. Of a total of 69 cases, orphenadrine was present in 57 (83%), biperiden in 8 (12%), procyclidine in 3 (4%), and trihexyphenidyl/benzhexol in 1 (1%) of the subjects. The measured concentrations were assessed in light of previously published data. Of 21 cases where causality between drug ingestion and death was classified as either highly probable (18/21) or possible (3/21), all subjects tested positive for orphenadrine. In the autopsy samples from these patients, orphenadrine concentrations in the 4.5-600 mumol/l range (mean 62.5 mumol/l, SD 126.5 mumol/l) were determined. Because of a low national autopsy rate, there is reason to believe that the actual numbers of drug-related deaths in this period may have been significantly higher. It is concluded that orphenadrine is responsible for a disproportionally high number of overdose deaths.
Asunto(s)
Antiparkinsonianos/envenenamiento , Relajantes Musculares Centrales/envenenamiento , Intoxicación/epidemiología , Adolescente , Adulto , Anciano , Antiparkinsonianos/sangre , Autopsia , Sobredosis de Droga , Humanos , Persona de Mediana Edad , Relajantes Musculares Centrales/sangre , Noruega/epidemiología , Orfenadrina/envenenamiento , SuicidioRESUMEN
Today, anticholinergic antiparkinsonian drugs are primarily used to ameliorate extrapyramidal side-effects induced by neuroleptic agents. Orphenadrine dominates quantitatively among these drugs in Norway, presumably because it is assumed to carry a lower risk of abuse. There are numerous reports of deaths following orphenadrine overdoses. Orphenadrine has complex pharmacokinetic properties and a narrow therapeutic index. After an overdose, it confers toxic effects of rapid onset to several organ systems. No specific and effective therapy for orphenadrine intoxication has been established. For the two other drugs in this class which are marketed in Norway, biperiden and benztropine, toxicity is mainly connected to their anticholinergic properties. Notably, no reports of lethalities after overdoses of biperiden seem to be available. A small number of accounts of deaths following benztropine intoxication have been published. Neither of these two agents, and benztropine in particular, has been subjected to comprehensive pharmacokinetic evaluations. The relatively extensive use of orphenadrine should be discouraged.
Asunto(s)
Antiparkinsonianos/envenenamiento , Relajantes Musculares Centrales/envenenamiento , Benzotropina/envenenamiento , Biperideno/envenenamiento , Sobredosis de Droga , Humanos , Orfenadrina/envenenamiento , Factores de RiesgoRESUMEN
We report two cases in which a medicolegal autopsy disclosed small and previously undiagnosed gliomas. The first case was a 38-year-old woman who was found dead in bed; her autopsy revealed a 1.3-cm low-grade astrocytoma in the right subthalamic area. The second case involved a 32-year-old man who drowned in shallow water after his canoe capsized. A 0.5-cm oligoden-droglioma of the left temporal lobe and a 0.1-cm ganglionic hamartoma of the hypothalamus were found. In both cases the tumors may, directly or indirectly, have been the underlying cause of death. We emphasize the importance of a thorough neuropathological examination for all cases of sudden unexpected death in which no extracerebral cause of death has been found.
Asunto(s)
Neoplasias Encefálicas/patología , Muerte Súbita/etiología , Glioma/patología , Adulto , Causas de Muerte , Resultado Fatal , Femenino , Medicina Legal , Hamartoma/patología , Humanos , Enfermedades Hipotalámicas/patología , MasculinoRESUMEN
The prognostic value of systemic methotrexate clearance (ClMTX) during high-dose therapy was evaluated in a cohort of 42 children with acute lymphocytic leukemia (ALL). As part of an extensive chemotherapy protocol, they had received a total of 293 methotrexate (MTX) infusions in the 6-8 g/m2 dose range. At the termination of the study, when they had all been followed up for 3.5 years or more, 26 of these patients were still in continuous complete remission, whereas 16 had suffered relapse. The intrapatient variability in ClMTX during the eight courses was up to six-fold. In 67% of the patients, the maximum level of ClMTX reached at least twice the minimum value. The coefficients of variation for the intra- and interindividual variability in ClMTX were 9-57% and 26-41%, respectively. The cumulative probability of relapse, estimated by the Kaplan-Meier procedure, was increased for patients with a high ClMTX during the initial treatment course, but the difference was not significant on a 5% level. There was no significant relationship between high individual median ClMTX and subsequent relapse of ALL. However, ClMTX during the initial infusion, the time-dependent mean for ClMTX, and the individual patient's median ClMTX, were significant predictors for event-free survival in a Cox proportional hazards regression analysis. The present study demonstrates gross pharmacokinetic variability and unpredictable values of ClMTX in subsequent courses after standardized administration of MTX to paediatric patients with ALL. In spite of the association between ClMTX and prognosis shown by some of the analyses, estimates of ClMTX rates may not necessarily be related to disease outcome in a way that can be exploited to the benefit of the individual patient.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Metotrexato/farmacocinética , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Adolescente , Antimetabolitos Antineoplásicos/uso terapéutico , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Tasa de Depuración Metabólica , Metotrexato/uso terapéutico , Proyectos Piloto , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangre , Valor Predictivo de las Pruebas , Probabilidad , Pronóstico , Recurrencia , Reproducibilidad de los Resultados , Medición de RiesgoRESUMEN
Thirty cases (breast cancer-20 cases, malignant lymphoma-4 cases, different malignancies-6 cases) of histologically/cytologically verified malignant pleural effusion (MPE) in 29 patients were treated with intrapleurally instilled mitoxantrone (30 mg). The therapy was well tolerated. At evaluation, 25 patients had died of progressive disease. The median survival was 3 months (range 0.3-21.3 months). There were 26 responders (12 complete responses (CR), 14 partial responses (PR)), whereas 4 patients relapsed and 3 of these had an early relapse (within 3 months). Patients achieving PR or CR had a low risk (15%) of treatment failure. Five patients were subjected to a pharmacokinetic evaluation. This demonstrated rapidly declining plasma and pleural exudate levels of mitoxantrone within the first 6 hours. At 24 hours after instillation, mitoxantrone was only detected in circulating mononuclear cells. This study shows that mitoxantrone is efficacious in the treatment of MPE, and may represent a cost-effective alternative.
Asunto(s)
Antineoplásicos/uso terapéutico , Mitoxantrona/uso terapéutico , Derrame Pleural Maligno/tratamiento farmacológico , Neoplasias Pleurales/secundario , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/farmacocinética , Neoplasias de la Mama/patología , Quimioterapia Adyuvante/economía , Análisis Costo-Beneficio , Drenaje , Exudados y Transudados/citología , Exudados y Transudados/metabolismo , Femenino , Estudios de Seguimiento , Humanos , Instilación de Medicamentos , Linfoma/patología , Masculino , Persona de Mediana Edad , Mitoxantrona/farmacocinética , Recurrencia Local de Neoplasia , Pleura , Derrame Pleural Maligno/metabolismo , Derrame Pleural Maligno/radioterapia , Neoplasias Pleurales/metabolismo , Neoplasias Pleurales/mortalidad , Estudios Retrospectivos , Tasa de SupervivenciaRESUMEN
Reports of a potentially life-threatening interaction between the antifolate methotrexate (MTX) and drugs belonging to the NSAID class instigated a study of MTX pharmacokinetics by a microdialysis technique in the presence and absence of the NSAID naproxen in anesthetized rats. After pretreatment with naproxen, the animals received either 750 or 1,000 mg/kg MTX as a 6 h continuous intravenous infusion. During infusions, microdialysis effluents were obtained from probes situated intravenously, intrahepatically and intrarenally. In all three compartments, time-concentration AUCs for both MTX and its major extracellular metabolite, 7-hydroxymethotrexate (7-OH-MTX), increased about two-fold in the presence of naproxen. The mechanisms responsible for the MTX-NSAID interaction are briefly discussed. The study demonstrate that the microdialysis technique offers a means to investigate pharmacokinetic drug-drug interactions.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Antimetabolitos Antineoplásicos/farmacocinética , Metotrexato/farmacocinética , Naproxeno/farmacología , Animales , Antagonistas del Ácido Fólico/sangre , Hidroxilación , Riñón/metabolismo , Hígado/metabolismo , Masculino , Metotrexato/análogos & derivados , Metotrexato/sangre , Microdiálisis , Ratas , Ratas WistarRESUMEN
A central tenet in oncology is the assumed relationship between drug concentration and cytotoxicity. Determinations of drug levels in tumor tissues are, however, generally not undertaken. Microdialysis is a method where continuous drug monitoring may be achieved by sampling of low molecular weight substances from the extracellular space. By employing this technique it is possible to observe variable drug levels within tissues, including tumors, over time. Herein, we present results from a nude rat model where subcutaneous human osteosarcoma xenografts were established prior to the administration of the antifolate methotrexate as an intravenous infusion. Significant differences in drug exposure within single tumors were evident. Generally, peak drug concentrations were lower and drug efflux slower from the center of the tumors as compared to the periphery. The use of microdialysis could be an important tool for optimizing current strategies in anticancer chemotherapy.